Our Prolaris clinical programs in Europe are also progressing well. Pro-009 is a clinical study from a German cohort of approximately 450 radical prostatectomy samples with the clinical endpoint of biochemical recurrence; and I am pleased to report it is ahead of schedule. We’ve received most of the prostate tumor samples for this study, expect to have results published next year. This represents our ninth clinical validation study on Prolaris.
Myriad Genetics' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts